Serious Early Childhood Wheezing After Respiratory Syncytial Virus Lower Respiratory Tract Illness in Preterm Infants

Clinical Therapeutics

Volumn 32, Issue 14, 2010, Pages 2422-2432

  Romero, José R ^a   Stewart, Dan L ^b,c   Buysman, Erin K ^d   Fernandes, Ancilla W ^e   Jafri, Hasan S ^e   Mahadevia, Parthiv J ^e  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^c KOSAIR CHILDREN'S HOSPITAL   (United States)

^d Ingenix Inc   (United States)

^e MEDIMMUNE   (United States)

Author keywords

Infants; Outcome measures; Premature; RSV; Wheezing

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR AFFECTING AGENT; METHYLXANTHINE;

ARTICLE; ASTHMA; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFANT; INFANT DISEASE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; OUTPATIENT CARE; PREMATURITY; PRESCHOOL CHILD; PREVALENCE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNITED STATES; WHEEZING;

CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; RESPIRATORY SOUNDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 79951846201     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.007     Document Type: Article

References (31)

1. Hall C.B. Respiratory syncytial virus. Textbook of Pediatric Infectious Diseases 1987, 1653-1675. Saunders, Philadelphia, Pa. 2nd ed. R.D. Feigen, J.D. Cherry (Eds.).
2. Hall C.B., Long C.E., Schnabel K.C. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001, 33:792-796.
3. Hall C.B., Weinberg G.A., Iwane M.K., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
4. Prospects for Immunizing Against Respiratory Synctial Virus 1985, Institute of Medicine, National Academy Press, Washington, DC.
5. Ruuskanen O., Ogra P.L. Respiratory syncytial virus. Curr Probl Pediatr 1993, 23:50-79.
6. Shay D.K., Holman R.C., Newman R.D., et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999, 282:1440-1446.
7. Leader S., Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002, 21:629-632.
8. Bont L., Aalderen W.M., Kimpen J.L. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr Respir Rev 2000, 1:221-227.
9. Pérez-Yarza E.G., Moreno A., Lázaro P., et al. The association between respiratory syncytial virus infection and the development of childhood asthma: A systematic review of the literature. Pediatr Infect Dis J 2007, 26:733-739.
10. Mohapatra S.S., Boyapalle S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev 2008, 21:495-504.
11. Meissner H.C., Long S.S. Respiratory syncytial virus infection and recurrent wheezing: A complex relationship. J Pediatr 2007, 151:6-7.
12. Simões E.A. RSV disease in the pediatric population: Epidemiology, seasonal variability, and long-term outcomes. Manag Care 2008, 17:3-6. discussion 18-19.
13. Respiratory Syncytial Virus. Red Book: 2006 Report of the Committee on Infectious Diseases 2006, 560-566. American Academy of Pediatrics, Elk Grove Village, Ill. 27th ed. L.K. Pickering, C.J. Baker, S.S. Long, J.A. McMillan (Eds.).
14. Simoes E.A., Groothuis J.R., Carbonell-Estrany X., et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007, 151:34-42. Palivizumab Long-Term Respiratory Outcomes Study Group, 42.e1.
15. Wenzel S.E., Gibbs R.L., Lehr M.V., Simoes E.A. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002, 112:627-633.
16. Henderson J., Hilliard T.N., Sherriff A., et al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr Allergy Immunol 2005, 16:386-392.
17. Sigurs N., Bjarnason R., Sigurbergsson F., Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000, 161:1501-1507.
18. Sigurs N., Gustafsson P.M., Bjarnason R., et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005, 171:137-141.
19. Stein R.T., Sherrill D., Morgan W.J., et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354:541-545.
20. Sigurs N., Bjarnason R., Sigurbergsson F., et al. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: A prospective cohort study with matched controls. Pediatrics 1995, 95:500-505.
21. National Asthma Education and Prevention Program. Expert panel report 3: Guidelines for the Diagnosis and Management of Asthma National Heart, Lung, and Blood Institute, US Department of Health and Human Services, Accessed January 20, 2011. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
22. International Statistical Classification of Diseases and Related Health Problems, Ninth Revision, Clinical Modification 2003, World Health Organization, WHO, Geneva, Switzerland.
23. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009, 124:1694-1701. Committee on Infectious Diseases.
24. Consumer Price Index, Chained Consumer Price Index 2006 Bureau of Labor Statistics, US Department of Labor, Accessed January 20, 2011. http://www.bls.gov/data/.
25. Manning W.G. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998, 17:283-295.
26. Stempel D.A., Kruzikas D.T., Manjunath R. Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast. J Pediatr 2007, 150:162-167.
27. Stempel D.A., Riedel A.A., Carranza Rosenzweig J.R. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. Curr Med Res Opin 2006, 22:463-470.
28. Eriksson M., Bennet R., Nilsson A. Wheezing following lower respiratory tract infections with respiratory syncytial virus and influenza A in infancy. Pediatr Allergy Immunol 2000, 11:193-197.
29. Korppi M., Kotaniemi-Syrjänen A., Waris M., et al. Rhinovirus-associated wheezing in infancy: Comparison with respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J 2004, 23:995-999.
30. Lemanske R.F. Viruses and asthma: Inception, exacerbation, and possible prevention. J Pediatr 2003, 142(Suppl 2):S3-S7. ; discussion S7-S8.
31. Current Procedural Terminology: 2001 2000, American Medical Association (AMA), AMA, Chicago, Ill.